Telomir Pharmaceuticals, Inc.
TELO
$1.26
-$0.03-2.33%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | 37.01% | 51.00% | 14.21% | 33.89% | -26.48% |
| Total Depreciation and Amortization | -- | -- | -- | -- | -- |
| Total Amortization of Deferred Charges | -- | -100.00% | -100.00% | -100.00% | 169.20% |
| Total Other Non-Cash Items | -12.39% | -32.16% | 74.14% | 11.84% | -6.54% |
| Change in Net Operating Assets | 370.49% | -452.97% | 88.75% | -73.55% | 10.97% |
| Cash from Operations | 27.26% | 44.30% | 51.66% | 21.12% | -31.36% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -104.80% | -100.00% | -100.00% |
| Total Debt Repaid | -- | -100.00% | 100.00% | 100.00% | -- |
| Issuance of Common Stock | 39.05% | 61.87% | -64.80% | -82.49% | 530.30% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | 100.00% | 153.40% | 116.71% | -69.53% |
| Cash from Financing | 53.25% | 50.18% | -75.80% | -86.53% | 64.14% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 375.97% | 680.43% | -160.43% | -187.74% | 632,550.00% |